Biospecimen/Pathology Core

生物样本/病理学核心

• 批准号: 10005928
• 负责人: JOSEPH EDWARD WILLIS
• 金额: $ 10.02万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005928
• 关键词: Advocacy; Africa; African; African American; Applications Grants; Archives; Bioinformatics; Blood; Blood specimen; Breast; Cancer Center; Cell Line; Clinical; Clinical Medicine; Clinical Pathology; Clinical Trials; Colon Carcinoma; Communities; Comprehensive Cancer Center; Consultations; DNA; Data; Data Set; Databases; Development; Disease; Education; Ensure; Ethnic Origin; Experimental Designs; Faculty; Formalin; Formulation; Freezing; Generations; Genomics; Goals; Grant; Growth; Histology; Human Resources; Immunohistochemistry; In Situ Hybridization; Incidence; Individual; Information Dissemination; Infrastructure; International; Laboratories; Leadership; Life Style; Link; Lung; Malignant Neoplasms; Mammary Gland Parenchyma; Manuscripts; Medical center; Microdissection; Minority; Mission; Molecular; Morphology; Oncology; Outcome; Ovary; Paraffin Embedding; Pathology; Patient advocacy; Patients; Phase; Play; Population; Population Heterogeneity; Positioning Attribute; Process; Prostate; Publications; Quality Control; Questionnaires; RNA; Race; Records; Research; Research Activity; Research Personnel; Research Project Grants; Resource Sharing; Resources; Role; Sampling; Schedule; Services; Specimen; System; Techniques; Technology; Testing; Tissue Embedding; Tissue Microarray; Tissue Procurements; Tissues; Translational Research; University Hospitals; Work; Writing; Xenograft procedure; adenoma; base; biobank; cancer health disparity; cancer subtypes; clinical data warehouse; colon cancer patients; cost effective; digital; experience; follow-up; high risk; insight; interest; kindred; laser capture microdissection; meetings; member; programs; prospective; skills; success; tissue resource

BIOSPECIMEN CORE ABSTRACT The Disparities Biospecimen Core will provide an array of services to promote the mission of this SPORE program and play a pivotal role in the nurturing of ongoing, proposed and developing cancer disparities research at Case Comprehensive Cancer Center [Case CCC] including provide crucial support for the projects and pilots related to this application. The Core directly participated in the generation of preliminary data for the projects and advised on the scope and direction of the submissions. The Core will actively engage in every aspect of programmatic development of the P20 SPORE into a full SPORE. This includes working with Case CCC Office of Cancer Disparities Research, Patient Advocacy and Community Advisory Boards. The directors of this Core are established leaders in clinical pathology with extensive records of commitment to translational research. They have extensive track records of working with the co-leaders of the P20 SPORE and project leaders. Given their institutional leadership positions, they are also positioned to facilitate further growth of Core engagement beyond the two initially targeted disease systems. The Core has established an array of annotated biospecimens of over 13,000 patients by combining the resources of the Case CCC GI and Breast Tissue Resources. This archive includes a combination of diverse biospecimens including over 1000 fresh frozen colon cancers, over 4,500 fixed colon cancers, 2600 blood samples from high risk kindreds of colon cancer patients, over 600 fixed adenomas as well as multiple cell lines and patient derived xenografts. The breast archive contains specimens from over 3500 patients. A large portion of these specimens have extended clinical follow-up and have undergone advanced molecular testing. The Core will work with Case CCC to make available a wide variety of techniques and technologies in a cost effective manner. The Core will organize prospective biospecimen procurements and distribution to SPORE investigators as well as provide access to its existing archive resource. The Core will provide histopathological quality control for tissue sections, along with project specific morphology case reviews and will oversee and provide longitudinal follow-up of clinical outcomes linked to these tissues. The Core will also provide tissue microarray sections for tissue targets of interest, expertise in immunohistochemistry and in situ hybridization assessment and samples appropriate for specific studies. The primary objective is to provide a resource that contributes significantly to the translational goals and endpoints of the individual projects and to facilitate cooperation between other SPORES.

生物样本核心摘要 差异生物样本核心将提供一系列服务，以促进该孢子的使命 计划并在培养正在进行的，拟议的和发展中的癌症差异方面发挥关键作用 在Case Comprehensive Cancer Center [Case CCC]进行研究，包括为项目提供关键支持 以及与该应用相关的飞行员。核心小组直接参与了为2010年12月21日至2011年12月31日期间的 项目，并就提交的范围和方向提供意见。核心将积极参与每一个 P20 SPORE的程序化开发方面成为一个完整的SPORE。这包括与Case合作 CCC癌症差异研究办公室，患者倡导和社区咨询委员会。董事 该核心的成员是临床病理学领域的公认领导者，他们在致力于翻译方面有着广泛的记录。 research.他们与P20 SPORE和项目的共同领导人有着广泛的合作记录 领导人的人选信号鉴于它们在机构中的领导地位，它们也有能力促进 核心参与超出了最初针对的两个疾病系统。核心已经建立了一系列 通过结合Case CCC GI和Breast的资源，对超过13，000名患者的生物样本进行注释 组织资源。这个档案包括各种生物标本的组合，包括1000多个新鲜的 冷冻结肠癌，超过4,500例固定结肠癌，2600例来自高风险结肠癌的血液样本 癌症患者，超过600个固定的腺瘤以及多种细胞系和患者来源的异种移植物。的 乳房档案包含来自3500多名患者的标本。这些标本中的很大一部分 临床随访，并进行了先进的分子检测。核心将与案例CCC合作， 以具有成本效益的方式提供各种各样的技术和工艺。核心会组织 为SPORE研究者提供前瞻性生物标本的采购和分发，并提供访问 现有的档案资源。Core将为组织切片提供组织病理学质量控制，沿着 进行项目特定形态学病例审查，并将监督和提供临床 与这些组织相关的结果。核心还将提供组织微阵列切片的组织目标， 对免疫组织化学和原位杂交评估感兴趣，具有专门知识， 具体研究。主要目标是提供一个资源，大大有助于翻译 目标和终点的各个项目，并促进其他SPORES之间的合作。